BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 26934318)

  • 1. Predictive role of microRNA-related genetic polymorphisms in the pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients.
    Dreussi E; Pucciarelli S; De Paoli A; Polesel J; Canzonieri V; Agostini M; Friso ML; Belluco C; Buonadonna A; Lonardi S; Zanusso C; De Mattia E; Toffoli G; Cecchin E
    Oncotarget; 2016 Apr; 7(15):19781-93. PubMed ID: 26934318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-31 Emerges as a Predictive Biomarker of Pathological Response and Outcome in Locally Advanced Rectal Cancer.
    Caramés C; Cristobal I; Moreno V; Marín JP; González-Alonso P; Torrejón B; Minguez P; Leon A; Martín JI; Hernández R; Pedregal M; Martín MJ; Cortés D; García-Olmo D; Fernández MJ; Rojo F; García-Foncillas J
    Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27271609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating serum microRNA-345 correlates with unfavorable pathological response to preoperative chemoradiotherapy in locally advanced rectal cancer.
    Yu J; Li N; Wang X; Ren H; Wang W; Wang S; Song Y; Liu Y; Li Y; Zhou X; Luo A; Liu Z; Jin J
    Oncotarget; 2016 Sep; 7(39):64233-64243. PubMed ID: 27572313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics Biomarkers and Their Specific Role in Neoadjuvant Chemoradiotherapy Treatments: An Exploratory Study on Rectal Cancer Patients.
    Dreussi E; Cecchin E; Polesel J; Canzonieri V; Agostini M; Boso C; Belluco C; Buonadonna A; Lonardi S; Bergamo F; Gagno S; De Mattia E; Pucciarelli S; De Paoli A; Toffoli G
    Int J Mol Sci; 2016 Sep; 17(9):. PubMed ID: 27608007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered levels of the onco-microRNA 21 and the tumor-supressor microRNAs 143 and 145 in advanced rectal cancer indicate successful neoadjuvant chemoradiotherapy.
    Drebber U; Lay M; Wedemeyer I; Vallböhmer D; Bollschweiler E; Brabender J; Mönig SP; Hölscher AH; Dienes HP; Odenthal M
    Int J Oncol; 2011 Aug; 39(2):409-15. PubMed ID: 21567082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy.
    Cecchin E; Agostini M; Pucciarelli S; De Paoli A; Canzonieri V; Sigon R; De Mattia E; Friso ML; Biason P; Visentin M; Nitti D; Toffoli G
    Pharmacogenomics J; 2011 Jun; 11(3):214-26. PubMed ID: 20368715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer.
    Della Vittoria Scarpati G; Falcetta F; Carlomagno C; Ubezio P; Marchini S; De Stefano A; Singh VK; D'Incalci M; De Placido S; Pepe S
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1113-9. PubMed ID: 22172905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of increasing radiation dose on pathologic complete response in rectal cancer patients treated with neoadjuvant chemoradiation therapy.
    Hall MD; Schultheiss TE; Smith DD; Fakih MG; Wong JY; Chen YJ
    Acta Oncol; 2016 Dec; 55(12):1392-1399. PubMed ID: 27762654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of differentiation and T stage can predict unresponsiveness to neoadjuvant therapy for rectal cancer.
    Qiu HZ; Wu B; Xiao Y; Lin GL
    Colorectal Dis; 2011 Dec; 13(12):1353-60. PubMed ID: 21689282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. XRCC1 gene polymorphism for prediction of response and prognosis in the multimodality therapy of patients with locally advanced rectal cancer.
    Grimminger PP; Brabender J; Warnecke-Eberz U; Narumiya K; Wandhöfer C; Drebber U; Bollschweiler E; Hölscher AH; Metzger R; Vallböhmer D
    J Surg Res; 2010 Nov; 164(1):e61-6. PubMed ID: 20863523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of thymidylate synthase polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy.
    Arrazubi V; Suárez J; Guerrero D; Gómez M; Viúdez A; Arias F; Balén E; Vera R
    Colorectal Dis; 2013 Apr; 15(4):428-35. PubMed ID: 22958523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of interval between neoadjuvant chemoradiotherapy and TME for locally advanced rectal cancer on pathologic response and oncologic outcome.
    Wolthuis AM; Penninckx F; Haustermans K; De Hertogh G; Fieuws S; Van Cutsem E; D'Hoore A
    Ann Surg Oncol; 2012 Sep; 19(9):2833-41. PubMed ID: 22451236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A single institution's long-term follow-up of patients with pathological complete response in locally advanced rectal adenocarcinoma following neoadjuvant chemoradiotherapy.
    Runau F; Collins A; Fenech GA; Ford E; Dimitriou N; Chaudhri S; Yeung JM
    Int J Colorectal Dis; 2017 Mar; 32(3):341-348. PubMed ID: 27885480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is adjuvant chemotherapy necessary for patients with pathological complete response after neoadjuvant chemoradiotherapy and radical surgery in locally advanced rectal cancer? Long-term analysis of 40 ypCR patients at a single center.
    Zhou J; Qiu H; Lin G; Xiao Y; Wu B; Wu W; Sun X; Lu J; Zhang G; Xu L; Liu Y
    Int J Colorectal Dis; 2016 Jun; 31(6):1163-8. PubMed ID: 27044403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive and prognostic biomarkers for neoadjuvant chemoradiotherapy in locally advanced rectal cancer.
    Lim SH; Chua W; Henderson C; Ng W; Shin JS; Chantrill L; Asghari R; Lee CS; Spring KJ; de Souza P
    Crit Rev Oncol Hematol; 2015 Oct; 96(1):67-80. PubMed ID: 26032919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Predictive factors associated with pathologic complete response after neoadjuvant chemoradiotherapy in rectal cancer].
    Sun Y; Chi P; Xu B; Lin H; Lu X; Huang Y; Xu Z; Huang S; Jiang C
    Zhonghua Wei Chang Wai Ke Za Zhi; 2014 Jun; 17(6):556-60. PubMed ID: 24953361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Genetic variations in MLH3 and MSH2 genes are associated with the sensitivity and prognosis in locally advanced rectal cancer patients receiving preoperative chemoradiotherapy].
    Yang J; Wang X; Zou SM; Li HM; Xiao Q; Feng YR; Huang Y; Feng T; Chen JN; Lin DX; Li YX; Jin J; Tan W
    Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):433-440. PubMed ID: 29936769
    [No Abstract]   [Full Text] [Related]  

  • 18. Can an IL13 -1112 C/T (rs1800925) polymorphism predict responsiveness to neoadjuvant chemoradiotherapy and survival of Chinese Han patients with locally advanced rectal cancer?
    Xiao L; Yu X; Zhang R; Chang H; Xi S; Xiao W; Zeng Z; Zhang H; Xu R; Gao Y
    Oncotarget; 2016 Jun; 7(23):34149-57. PubMed ID: 27167201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients.
    Sclafani F; Chau I; Cunningham D; Lampis A; Hahne JC; Ghidini M; Lote H; Zito D; Tabernero J; Glimelius B; Cervantes A; Begum R; De Castro DG; Wilson SH; Peckitt C; Eltahir Z; Wotherspoon A; Tait D; Brown G; Oates J; Braconi C; Valeri N
    Carcinogenesis; 2016 Sep; 37(9):852-7. PubMed ID: 27381831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global DNA methylation is altered by neoadjuvant chemoradiotherapy in rectal cancer and may predict response to treatment - A pilot study.
    Tsang JS; Vencken S; Sharaf O; Leen E; Kay EW; McNamara DA; Deasy J; Mulligan ED
    Eur J Surg Oncol; 2014 Nov; 40(11):1459-66. PubMed ID: 25108814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.